Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Hypoxia 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 86Cyclophosphamide 58Carboplatin 57Specimen Handling 55fludarabine 45Nivolumab 45Magnetic Resonance Spectroscopy 44Gemcitabine 41Biopsy 40Bevacizumab 36Dexamethasone 31venetoclax 30Paclitaxel 29Cisplatin 29Pemetrexed 28Injections 28Docetaxel 26atezolizumab 24Ipilimumab 23Capecitabine 22Temozolomide 21Azacitidine 21Oxaliplatin 20Cetuximab 20Rituximab 19Lenalidomide 19Fulvestrant 19abemaciclib 18Fluorouracil 17Vincristine 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Tirapazamine × 90 days × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡